Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
SONNPRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC at its special meeting of stockholders.
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
SONNPRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting of stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on its proposed business combination (the “Business Combination”) with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC (“Rorschach”), and the other proposals to be considered at the special meeting.
Sonnet Releases Virtual Investor "What This Means" Segment
SONN- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Sonnet BioTherapeutics Q2 EPS $(0.89) Misses $(0.79) Estimate
SONNChardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target
SONNSonnet BioTherapeutics Holdings Announces Safety Results Of Son-1010 At Highest Dose Combined With Atezolizumab In Phase 1b/2a Clinical Trial In Adult Patients With Advanced Solid Tumors Or Platinum-resistant Ovarian Cancer
SONNSonnet BioTherapeutics Reveals Passing Of Founder And CEO Pankaj Mohan; Appoints Current Board Member Raghu Rao As Interim CEO
SONNChardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target
SONNSonnet BioTherapeutics Announces Safety Review Results Of SON-1010 In Combination With Trabectedin For Advanced Soft Tissue Sarcomas, Showing No Unexpected Toxicities And Clinical Benefit In 83% Of Patients, Paving The Way For Full Enrollment In Phase 1 S
SONNSonnet BioTherapeutics Receives Notice Of Allowance For U.S. Patent Covering Composition Of Matter Of Specific Amino Acid Substitutions Of Its IL-18 Binding Protein Resistant Variant Protein
SONNSonnet BioTherapeutics Announces Presentation Of Data At 2025 AACR IO Conference Featuring FHAB Platform Strategy Compilation For First Time
SONNSonnet BioTherapeutics Announces Plans To Advance The Development Of Its Antibody Drug Conjugate Platform
SONNSonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate
SONNSonnet BioTherapeutics CFO Resigns Effective Feb. 21, 2025; Co Names Donald Griffith As Successor
SONNChardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20
SONNSonnet BioTherapeutics Prices $5M Public Offering At-The-Market Under Nasdaq Rules, Selling 1.11M Shares And Warrants For Additional 2.22M Shares At $4.50 Per Share
SONNSonnet BioTherapeutics Shares Resume Trading
SONNSonnet BioTherapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 85.3%
SONNSonnet BioTherapeutics Shares Resume Trade
SONNSonnet BioTherapeutics shares are trading higher after the company announced the issuance of a U.S. patent covering an IL-18 variant into two novel immunotherapeutic drug candidates.
SONNSonnet BioTherapeutics Shares Halted On Circuit breaker To The Downside, Stock Now Up 106.9%
SONNSonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Co
SONNEF Hutton Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $7
SONN